Particle.news
Download on the App Store

Quoin Pharmaceuticals Shares Jump on $104.5 Million Private Placement With $16.8 Million Upfront

The rare-disease developer plans to use the premium-priced funding, set to close around Oct. 14, to advance QRX003 for Netherton Syndrome.

Overview

  • Quoin announced a private placement that could raise up to $104.5 million through a mix of American Depositary Shares, pre-funded warrants, and four series of additional warrants.
  • The deal includes an immediate $16.8 million from new and existing institutional investors, providing near-term capital.
  • Net proceeds are earmarked for general corporate purposes, research and development, and completing clinical development of QRX003.
  • Shares surged intraday to about $20.40, up roughly 149%, after the company said the placement was priced at a premium to the prior close of $8.16.
  • The transaction is expected to close on or about Oct. 14, with the ultimate proceeds dependent on future warrant exercises.